Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Allecra Therapeutics

Request full access

Novel antibiotics to combat drug-resistant bacterial infections

Saint-Louis, FranceFounded 2011Biotech & Life Sciences

About Allecra Therapeutics

Allecra Therapeutics is a clinical-stage biopharmaceutical company that develops therapies to combat antibiotic resistance in gram-negative bacteria.

The company's lead product, EXBLIFEP®, is a combination of enmetazobactam, a novel beta-lactamase inhibitor, and the cephalosporin cefepime. This combination is designed to be effective against multi-drug-resistant (MDR) gram-negative bacteria. The U.S. Food and Drug Administration (FDA) has approved EXBLIFEP® for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older. The company's business model is focused on the development and commercialization of this and other novel antibiotic treatments. Allecra Therapeutics operates in the biopharmaceutical market, specifically targeting infectious diseases and antibiotic resistance. The company collaborates with other pharmaceutical companies for the commercialization of its products in different regions.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
62.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Infections and Infectious Diseases, Bacteria, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, radar de l'innovation, DT and LS, observatoire healthtech
Business model
Manufacturing

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jun 2016 $24M $97M Andera Partners · Nicholas Benedict · Forbion Capital Partners · EMBL Ventures ↗
SERIES AOther financing Apr 2015 $17M $66M EMBL Ventures · Andera Partners —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Allecra Therapeutics website traffic

Latest recorded traffic for Allecra Therapeutics is 300 monthly website visits, down 84.2% over the last three months. Allecra Therapeutics's team grew 0% over the past year.

Latest monthly visits300 3-month web change-84.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Pherecydes PharmaOperator of an innovative biotechnologies company created to develop personalized phage therapy Nantes, France Closed 4 $18M $35M
FabentechSpecializes in the development and production of emergency treatments to combat the risks of bioterrorism and emerging infectious diseases that are priorities for public health Lyon, France Operational
AntabioAntabio is a clinical-stage biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO Labège, France Operational
Eligo BioscienceEligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing Paris, France Operational
Signia TherapeuticsProposes a breakthrough strategy to identify and repurpose rapidly, efficiently, and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses Lyon, France Closed
SensorionDeveloping life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss Montpellier, France Operational
Amolyt PharmaMultinational group of biopharmaceutical companies developing drugs, proteins and peptides Écully, France Acquired
GenSensorTherapeutic progress and patient access to new biotherapies now rely on bioproduction capacity and … Home Read More » Saint-Herblain, France Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Allecra Therapeutics in the Saint-Louis ecosystem

Live from Dealroom

The Allecra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • EMBL Ventures
  • Andera Partners
  • Delos Capital
  • Nicholas Benedict
  • Forbion Capital Partners
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇫🇷 France50%
🇨🇭 Switzerland25%
🇩🇪 Germany25%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Allecra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Allecra Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.